Several studies have indicated that the PCA3 test is useful in reducing the number of negative biopsies34, 39, 51, and more recently the FDA approved the PROGENSA PCA3 assay as a new test for prostate cancer. This evidence concerns the gene PCA3 and prostate cancer.